Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giuseppe Rosano, David Quek, Felipe Martínez
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/58046a30dfdd462285494bac6b076e2c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:58046a30dfdd462285494bac6b076e2c
record_format	dspace
spelling	oai:doaj.org-article:58046a30dfdd462285494bac6b076e2c2021-12-04T16:03:44ZSodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice10.15420/cfr.2020.232057-75592057-7540https://doaj.org/article/58046a30dfdd462285494bac6b076e2c2020-11-01T00:00:00Zhttps://www.cfrjournal.com/articleindex/cfr.2020.23https://doaj.org/toc/2057-7540https://doaj.org/toc/2057-7559Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary hospitalisation due to heart failure and cardiovascular death in these patients. Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have demonstrated the positive clinical impact of SGLT2 inhibition in patients with heart failure with reduced ejection fraction both with and without T2D. These data have led to the approval of dapagliflozin for the treatment of patients with heart failure with reduced ejection fraction, irrespective of T2D status. This article reviews the latest data reported from the DAPA-HF and EMPEROR-Reduced trials and their clinical implications for the treatment of patients with heart failure.Giuseppe RosanoDavid QuekFelipe MartínezRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENCardiac Failure Review , Vol 6, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Giuseppe Rosano David Quek Felipe Martínez Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
description	Heart failure is a shared chronic phase of many cardiac diseases and its prevalence is on the rise globally. Previous large-scale cardiovascular outcomes trials of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) have suggested that these agents may help to prevent primary and secondary hospitalisation due to heart failure and cardiovascular death in these patients. Data from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure (DAPA-HF) and Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) have demonstrated the positive clinical impact of SGLT2 inhibition in patients with heart failure with reduced ejection fraction both with and without T2D. These data have led to the approval of dapagliflozin for the treatment of patients with heart failure with reduced ejection fraction, irrespective of T2D status. This article reviews the latest data reported from the DAPA-HF and EMPEROR-Reduced trials and their clinical implications for the treatment of patients with heart failure.
format	article
author	Giuseppe Rosano David Quek Felipe Martínez
author_facet	Giuseppe Rosano David Quek Felipe Martínez
author_sort	Giuseppe Rosano
title	Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
title_short	Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
title_full	Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
title_fullStr	Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
title_full_unstemmed	Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
title_sort	sodium–glucose co-transporter 2 inhibitors in heart failure: recent data and implications for practice
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/58046a30dfdd462285494bac6b076e2c
work_keys_str_mv	AT giusepperosano sodiumglucosecotransporter2inhibitorsinheartfailurerecentdataandimplicationsforpractice AT davidquek sodiumglucosecotransporter2inhibitorsinheartfailurerecentdataandimplicationsforpractice AT felipemartinez sodiumglucosecotransporter2inhibitorsinheartfailurerecentdataandimplicationsforpractice
_version_	1718372735629918208

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice

Ejemplares similares